Categories: All postsSoftware

OpenText stock is much more attractive than Constellation Software, Teal Linde says

The last couple of months have been a rough ride for investors in the tech sector, but if you’re looking for a solid pick from here on out, try Canada’s own OpenText (OpenText Stock Quote, Chart NASDAQ, TSX:OTEX), says portfolio manager Teal Linde.

“I think it’s a great company, very successful,” says Linde, manager at Linde Equity Fund, to BNN Bloomberg. “The stock has come off recently because there have been concerns that they’re going to run out of acquisition targets. And so, management has come out and said that they can identify about $100 billion worth of acquisitions targets.”

“They’re generating decent cash flow and they have about $1.5 billion of acquisition capacity. So I think it’s more attractive than Constellation Software, given that the valuation is much more reasonable,” he says.

OTEX’s share price is virtually even for the year, having started out 2018 at C$44.61 before climbing to a high of $51.98 by early August, only to sink again with the broader tech selloff to where it currently sits at C$45.03 as of late Tuesday trading. Before this year, however, the stock saw a good half-decade of growth, starting in early 2013 when OTEX was priced in the C$14 range.

A serial acquirer, OpenText’s latest major purchase was cloud-based enterprise information management company Liaison Technologies, announced on October 31 with the purchase price of $310 million, all in cash. (All figures in US dollars unless otherwise noted.)

For the company’s latest quarterly report, its fiscal first quarter of 2019, also delivered on October 31, OpenText posted a profit of $36.3 million or 14 cents per share, down less than one per cent year-over-year. Revenue came in at $667 million, which was up four per cent year-over-year but was below analysts’ consensus expectation of $689 million. In August, management issued a restructuring plan which aimed at improving the company’s profitability.

“I am pleased with our Q1 Fiscal 2019 results, as OpenText expanded margins and strengthened its balance sheet,” said OpenText EVP, CFO, Madhu Ranganathan, in a press release to mark the first quarter. “We remain focused in our approach to scaling productivity and continuous improvement. We are successfully executing towards our recently announced restructuring plan. Our balance sheet and liquidity position remain very strong with approximately $788 million of cash at the end of the quarter, a 1.7x consolidated net leverage ratio, giving us the flexibility to further support our Total Growth strategy.”

Tagged with: otex
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Buy Graham Corporation on the pullback, analyst says

Beacon Securities analyst Russell Stanley reiterated his “Buy” rating and $130.00 target on Graham Corporation (Graham Corporation Stock Quote, Chart,… [Read More]

12 hours ago

iFabric is just getting started, this analyst says

Beacon Securities analyst Doug Cooper says iFabric’s (iFabric Stock Quote, Chart, News, Analysts, Financials TSX:IFA) medical scrubs opportunity is being… [Read More]

13 hours ago

MDA Space stock is a double from here, analyst says

Beacon Securities analyst Russell Stanley reiterated his “Buy” rating and street-high $88.00 target on MDA Space (MDA Space Stock Quote,… [Read More]

16 hours ago

Can Hammond Power stock go even higher?

National Bank Financial analyst Baltej Sidhu raised his target on Hammond Power Solutions (Hammond Power Solutions Stock Quote, Chart, News,… [Read More]

17 hours ago

What’s going on with Canada’s job losses?

RBC senior economist Claire Fan says Canada’s September job losses were concentrated among younger workers and should not be overread.… [Read More]

18 hours ago

This biotech stock has a massive upside, Roth says

Roth Capital Partners analyst Adam Walsh says a third controlled celiac disease dataset supporting IL-15 blockade increases the potential value… [Read More]

19 hours ago